论文部分内容阅读
目的:探讨原发性肝癌经肝动脉灌注化疗栓塞术(transcatheter arterial chemo-embolization,TACE)治疗前影像学表现与治疗效果的相关性,为TACE术前预测治疗效果提供参考。方法:65例肝癌患者TACE前CT表现分为均匀强化型、不均匀强化型、强化不明显型和无强化型),分析这4种CT表现对TACE治疗效果的相关性。结果:①65例患者近期疗效有效者28例(43.08%),无效37例(56.92%)。不同CT分型的肝癌患者行TACE近期疗效差异显著(P<0.05),其中均匀强化型的近期疗效均显著优于其他CT分型(P<0.05);②65例患者的6个月、12个月和24个月生存率分别为83.08%、66.15%和26.15%。不同CT分型的肝癌患者行TACE远期疗效差异显著(P<0.05),其中均匀强化型患者远期疗效均显著优于其他CT分型(P<0.05)。结论:原发性肝癌肝CT表现与TACE治疗效果具有相关性,CT表现可以进行原发性肝癌血供评估,可以初步预测原发性肝癌TACE的治疗效果。
Objective: To investigate the correlation between the imaging findings and the therapeutic effect of transcatheter arterial chemo-embolization (TACE) before the treatment of primary hepatocellular carcinoma (HCC), so as to provide a reference for predicting the therapeutic effect of TACE preoperatively. Methods: Sixty-five patients with hepatocellular carcinoma before TACE were divided into two groups: homogeneous enhancement, non-uniform enhancement, enhancement of non-obvious enhancement and non-enhancement. The correlation between these four CT findings and the effect of TACE was analyzed. Results: (1) 65 cases were effective in 28 cases (43.08%), 37 cases (56.92%) were ineffective. The short-term curative effect of TACE in patients with different types of liver cancer was significantly different (P <0.05). The short-term curative effect of homogenized intensive type was significantly better than that of other CT types (P <0.05). ② Six months and 12 The monthly and 24-month survival rates were 83.08%, 66.15% and 26.15% respectively. The long-term curative effect of TACE in patients with different types of liver cancer was significantly different (P <0.05). The long-term curative effect of homozygous patients was significantly better than that of other CT types (P <0.05). Conclusion: The CT findings of hepatocellular carcinoma in primary liver cancer are correlated with the therapeutic effect of TACE. The CT manifestations can be used to evaluate the blood supply of primary liver cancer and can predict the therapeutic effect of TACE in primary hepatocellular carcinoma.